Mammography screening is harmful and should be abandoned

Journal of the Royal Society of Medicine

Volumn 108, Issue 9, 2015, Pages 341-345

  Gøtzsche, Peter C ^a  

^a University of Copenhagen   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; FALSE POSITIVE RESULT; HUMAN; MAMMOGRAPHY; OVERDIAGNOSIS; PREDICTIVE VALUE; RADIATION HAZARD; RADIATION SAFETY; RADIODIAGNOSIS; TUMOR VOLUME; ADVERSE EFFECTS; BREAST NEOPLASMS; DENMARK; EPIDEMIOLOGY; FEMALE; LABORATORY DIAGNOSIS; MASS SCREENING; METASTASIS; MORTALITY; PATHOLOGY; QUALITY ADJUSTED LIFE YEAR; UTILIZATION;

BREAST NEOPLASMS; DENMARK; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; MAMMOGRAPHY; MASS SCREENING; NEOPLASM METASTASIS; QUALITY-ADJUSTED LIFE YEARS;

EID: 84960436087     PISSN: 01410768     EISSN: 17581095     Source Type: Journal    
DOI: 10.1177/0141076815602452     Document Type: Article

References (25)

1. Gøtzsche PC and Jørgensen KJ. Screening for breast cancer with mammography. Cochrane Database Syst Rev 2013; 6: CD001877 (first published in 2001).
2. Humphrey LL, Helfand M, Chan BK and Woolf SH. Breast cancer screening: a summary of the evidence for the U. S. Preventive Services Task Force. Ann Intern Med 2002; 137: 347-360.
3. Canadian Task Force on Preventive Health Care, Tonelli M, Connor Gorber S, Joffres M, Dickinson J, Singh H, Lewin G, et al. Recommendations on screening for breast cancer in average-risk women aged 40-74 years. CMAJ 2011; 183: 1991-2001.
4. Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet 2012; 380: 1778-1786.
5. Biller-Andorno N and Jüni P. Abolishing mammography screening programs? A view from the Swiss Medical Board. N Engl J Med 2014; 370: 1965-1967.
6. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
7. Gøtzsche PC. Relation between breast cancer mortality and screening effectiveness: systematic review of the mammography trials. Dan Med Bull 2011; 58: A4246.
8. Gøtzsche PC. Mammography screening: truth, lies and controversy. London: Radcliffe, 2012.
9. Gøtzsche PC, Jørgensen KJ, Zahl PH and Mæhlen J. Why mammography screening has not lived up to expectations from the randomised trials. Cancer Causes Control 2012; 23: 15-21.
10. Autier P, Boniol M, Middleton R, Doré JF, Héry C, Zheng T, et al. Advanced breast cancer incidence following population-based mammographic screening. Ann Oncol 2011; 22: 1726-1735.
11. Kalager M, Adami HO, Bretthauer M and Tamimi RM. Overdiagnosis of invasive breast cancer due to mammography screening: results from the Norwegian screening program. Ann Intern Med 2012; 156: 491-499.
12. Bleyer A and Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med 2012; 367: 1998-2005.
13. Jørgensen KJ and Gøtzsche PC. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. BMJ 2009; 339: b2587.
14. Jørgensen KJ, Zahl PH and Gøtzsche PC. Breast cancer mortality in organised mammography screening in Denmark: comparative study. BMJ 2010; 340: c1241.
15. Kalager M, Zelen M, Langmark F and Adami HO. Effect of screening mammography on breast-cancer mortality in Norway. N Engl J Med 2010; 363: 1203-1210.
16. Autier P, Boniol M, Gavin A and Vatten LJ. Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database. BMJ 2011; 343: d4411.
17. Bleyer A. US breast cancer mortality is consistent with European data. BMJ 2011; 343: d5630.
18. Jørgensen KJ, Zahl PH and Gøtzsche PC. Overdiagnosis in organised mammography screening in Denmark: a comparative study. BMC Womens Health 2009; 9: 36.
19. Zahl PH, Jørgensen KJ and Gøtzsche PC. Overestimated lead times in cancer screening has led to substantial underestimation of overdiagnosis. Br J Cancer 2013; 109: 2014-2019.
20. Pharoah PD, Sewell B, Fitzsimmons D, Bennett HS and Pashayan N. Cost effectiveness of the NHS breast screening programme: life table model. BMJ 2013; 346: f2618.
21. Baum M. Harms from breast cancer screening outweigh benefits if death caused by treatment is included. BMJ 2013; 346: f385.
22. Brodersen J and Siersma VD. Long-term psychosocial consequences of false-positive screening mammography. Ann Fam Med 2013; 11: 106-115.
23. Raftery J and Chorozoglou M. Possible net harms of breast cancer screening: updated modelling of Forrest report. BMJ 2011; 343: d7627.
24. Swiss Medical Board. Systematisches Mammographie- Screening. See www. medicalboard. ch/fileadmin/docs/ public/mb/Fachberichte/2013-12-15_Bericht_Mammo graphie_Final_Kurzfassung_e. pdf (last checked 15 December 2013).
25. Jørgensen KJ, Keen JD and Gøtzsche PC. Is mammographic screening justifiable considering its substantial overdiagnosis rate and minor effect on mortality? Radiology 2011; 260: 621-627.